Navigation Links
Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
Date:7/16/2008

oducing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

Contact:

Daiichi Sankyo Co., Ltd.

3-5-1, Nihonbashi Honcho, Chuo-ku,

Tokyo 103-8426, Japan

Masaya Tamae

Director-Public Relations Group, Corporate Communications Department

Tel: +81-3-6225-1126

Ranbaxy

Plot 90, Sector 32, Gurgaon

Haryana122001, India

Ramesh L. Adige

Executive Director-Corporate Affairs and Global Corporate Communications

email: ramesh.adige@ranbaxy.com

Tel: +91-124-4135000

Or

Raghu Kochar

Director-Corporate Communications

email: raghu.kochar@ranbaxy.com

Tel: +91-124-4135141

Mobile: 9811617256

Or

Krishnan Ramalingam

Sr. Manager-Corporate Communications

email: krishnan.ramalingam@ranbaxy.com

Tel: +91-124-4135143

Mobile: 9810042540


'/>"/>
SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
2. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
3. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
4. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
5. Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
6. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
7. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
8. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
9. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
10. Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol
11. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...FREMONT, Calif., Nov. 5 ...S), a leading developer of state-of-the-art geneti...er Sears, Ph.D. has joined the company,s Scientifi...designing and commercializing novel molecular diag...s, and on the development of computational biology...
(Date:11/5/2009)... LASIK Surgery and vision corre... directory were actively involved at the recently ...2009 Annual Meeting in San Francisco, California. ...MD, Dr. Jonathan Davidorf, MD, Dr. Peter Rapoza, M..., Dr. R. Wayne Bowman, MD, Dr. Edward Manche, MD, ...
(Date:11/4/2009)...HUNTSVILLE, Ala., Nov. 4 DIATHERIX...om ), today presented at the Michigan Security Ne...ce in Dearborn, Mich. Dennis Grimaud, Chairman and...he impact of the company,s advanced molecular diag...nse, infectious disease diagnosis and military eff...
(Date:11/4/2009)...SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ ...rted its financial results for the third quarter e...uarter ended September 30, 2009 improved to $31.0 ...oss of $37.0 million or $0.40 per share in the thi...ake improvements to its operating efficiencies as ...
Breaking Biology Technology:WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9DIATHERIX Laboratories Presents at Homeland Security Conference 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10
...ociates, Inc.,administrator for the HealthShares(T...the HealthShares(TM) Exchange-Traded Funds, today ... on Tuesday February 26, 2008, KV,Pharmaceutical C...ls, Inc.,(NYSE: BDY ) in the HealthShares(TM) Der...quired by Nycomed US Inc., a subsidiary of Nycomed...
...ration,(Nasdaq: BPUR ) today announced its financ...uary 31, 2008. For the quarter, the company report... share, compared with a net loss,of $6.9 million, ...eriod in,2007. Class A common shares outstanding o...,543,025, respectively., Revenues, Total revenue...
...ntered into an Agreement Under, Which Genmab Will ...ted in Brooklyn Park, Minnesot...ifornia, February 21, Genmab A/S (OMX: GEN) and PD... that they have entered into an agreement,under wh...ing facility,located in Brooklyn Park, Minnesota, ...
Other Biology Technology:Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5
(Date:11/4/2009).... Louis, MO, November 4, 2009 Childhood obesity i...ns. With more than one fourth of advertising on da...nd beverages and continuing questions about the ro...ember/December issue of the Journal of Nutrition ...ing aimed at children might be a large contributor...
(Date:11/4/2009)..., PORTOLA VALLEY, Calif., Oct. 19 ...olecular sensing and imaging devices which shed li...that it has signed exclusive distribution deals fo...nsors. The markets covered include Australia, New...enelux), Suriname, Italy, France, Spain, Portugal,...
(Date:11/4/2009)..., RIDGE, N.Y., Oct. 21 What,s the ...eventing accidental death resulting from prescript...s with good intentions, however, may be unaware th...ting their teens from the ticking timebomb of pres...leader in premium-quality medical supplies, has fo...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Spectros Signs New International Distribution Deals 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3AMA Medicare Campaign Kicks Off With New TV Ads 59585 1AMA Medicare Campaign Kicks Off With New TV Ads 59585 2AMA Medicare Campaign Kicks Off With New TV Ads 59585 3Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 1Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 2ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 1ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 2
...of Standards and Technology (NIST) last week issue... and growing field of tissue engineering for medic...al tissue scaffold material that have been measure...es of porosity. , Three-dimensional tissue scaffo...adable materials that are meant to be implanted in...
...nt pieces of the climate change puzzle together is...is a key piece of this puzzle, but the size and sh...opardises the reliability of all current predictio...ct has been launched at the University of Leeds to...te. , Aerosols are small particles suspended in...
...f melanin -- the color pigment in skin and hair --...sed susceptibility to nicotine dependence and toba...rs, according to scientists., "We have found that...to the number of cigarettes smoked daily, levels o... African Americans," said Gary King, professor of ...
Other Biology News:NIST issues first reference material for tissue engineering 2Aerosol: A key piece of the climate change puzzle 2Skin color clue to nicotine dependence 2
Anti-Mouse VEGF-C Antibody, Unconjugated from Raybiotech, Inc.
Annexin V Binding Buffer from BD Biosciences Pharmingen
Mouse Anti-Cytokeratin 8 + 18 + 19 Monoclonal Antibody, Unconjugated, Clone 2A4 from Abcam
Tube-O-DIALYZER Floats, Floats, Small from CHEMICON
Biology Products: